TG Therapeutics Inc vs Trade Desk Inc — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Trade Desk Inc trades at $13.45 (market cap $6.37B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | TTD | |
|---|---|---|
Market Cap | $7.64B | $6.37B |
Sector | Health | Technology |
52-Week High | $59.06 | $55.36 |
52-Week Low | $26.94 | $13.39 |
Enterprise Value | $7.84B | $5.32B |
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
The Trade Desk (TTD) trades at $13.66, down 90% from its 2024 peak, with bearish technical signals and recent earnings misses. Revenue growth slowed to 3% in Q2 2026, and Q3 guidance projects a 12% decline. Despite strong profitability margins (net margin 13.6%), the stock faces execution challenges and advertiser pressure. Analyst sentiment is mixed with a $13.87 price target, while institutional selling and downgrades reflect mounting concerns.
Outlook remains cautious amid weak guidance and competitive threats, though current valuations (P/E 16.1) may attract value investors. Key risks include persistent revenue declines and market share erosion. Recovery hinges on stabilizing advertiser relationships and reversing recent execution gaps.
Trailing returns across standard periods
Latest headlines on both assets
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →